In January 2024, Stanford published the MISTIC study in Nature Medicine: 30 special operations veterans with PTSD and traumatic brain injury, treated with ibogaine, dramatic symptom reductions at one month. It got real coverage. What came next, eighteen months later, barely registered.

Key takeaways
  • A July 2025 paper in Nature Mental Health used EEG and neuroimaging to track what ibogaine actually does to brain activity in the same 30 SOCOM veterans from the original MISTIC trial.
  • After treatment, brain waves measurably slowed: theta and alpha power increased, beta and gamma decreased. Neural complexity dropped. These changes persisted at one-month follow-up.
  • Critically, the neurophysiological changes correlated directly with symptom improvements in PTSD, anxiety, and executive function, suggesting a biological mechanism rather than placebo or expectation effects.
  • Same limitations apply: 30 people, no control group, open-label. This is still early-stage science. But it is peer-reviewed neuroscience published in a Nature journal.

In July 2025, the same Stanford team published a follow-on paper in Nature Mental Health (DOI: 10.1038/s44220-025-00463-x). They had collected EEG data and neuroimaging scans from those same 30 veterans before treatment, 3.5 days after, and one month after. The question was simple: what is ibogaine actually doing to the brain?

The answer was measurable. After treatment, the veterans' brains showed a consistent pattern: slower oscillations increased in power (theta and alpha bands up), faster oscillations decreased (beta and gamma bands down). The theta-to-beta ratio rose, and that rise correlated with improved cognitive inhibition. Neural complexity, a measure of how chaotically varied brain activity is at rest, dropped significantly, and that reduction persisted at the one-month mark. These neurophysiological shifts tracked directly with the clinical improvements in PTSD severity, anxiety, and executive function.

Why This Matters Specifically for TBI

Most PTSD treatments are psychological interventions. Talk therapy, EMDR, prolonged exposure. They work on the mind's relationship to memory and trauma. For veterans whose PTSD is entangled with traumatic brain injury, that approach runs into a wall: TBI is physical. It is structural damage to the brain, the kind that does not resolve through behavioral retraining alone.

What the neuroimaging paper shows is that ibogaine is not just interrupting a psychological pattern. It is changing how the brain operates at a measurable, biological level. The "slowing" of cortical oscillations, the reduced complexity, the theta shifts: these are not self-reported outcomes. They are readings off a machine. For TBI specifically, the suggestion that ibogaine may promote something closer to neural repair, rather than symptom management, is the finding that deserves attention.

The original MISTIC paper mentioned GDNF, a protein that promotes neuron survival and growth, as a candidate mechanism. This neuroimaging paper doesn't close that loop, but it adds a layer of evidence that something structural is happening. The brain after ibogaine, by the measurements available, looks different. Not metaphorically. On an EEG.

What This Does Not Prove

The usual caveats apply, and they matter. Thirty people is not a large sample. There is no control group, so separating the effect of ibogaine from the therapeutic context, travel, structured time to process, medical attention, and expectation is not possible with this study design. Open-label trials of psychedelic treatments face a structural challenge: you cannot convincingly blind participants to whether they received ibogaine. These are not flaws unique to this study. They are inherent to this phase of research.

What this paper adds is mechanism. The criticism most commonly leveled at ibogaine research is that dramatic symptom self-reports are hard to interpret without understanding why. This study begins to answer the why, in the kind of language that neuroscience takes seriously: brain waves, oscillation patterns, complexity measures, peer review, a Nature journal.

The same controlled trials that will eventually confirm or complicate these findings are now in the pipeline, funded in part by the federal momentum following the Trump executive order on veteran psychedelic research. That process will take years. In the meantime, if you want to understand what ibogaine is doing to the veterans who say it changed their lives, this paper is worth knowing about.

Sources

  1. Williams NR, et al. "Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury." Nature Mental Health, vol. 3, July 24, 2025, pp. 918-931. DOI: 10.1038/s44220-025-00463-x
  2. Cherian KN, et al. "Magnesium-ibogaine therapy in veterans with traumatic brain injuries." Nature Medicine, vol. 30, January 2024, pp. 373-381. DOI: 10.1038/s41591-023-02705-w

IbogaineAdvisor.com is an editorially independent publication. Nothing here constitutes medical advice. About how we work.